Our study further establishes the impact of SLC7A5/SLC3A2 co-expression on the clinical outcome and efficacy of adjuvant endocrine treatment in a large cohort of patients with ER+ breast cancer. This evidence concerns the gene SLC3A2 and breast cancer.